|Title of host publication||Diapedia : The Living Textbook of Diabetes|
|Publisher||European Association for the Study of Diabetes (EASD)|
|Publication date||22 Dec 2014|
|Publication status||Published - 22 Dec 2014|
Pancreatic effects of GLP-1
Research output: Chapter in Book/Report/Conference proceeding › Encyclopedia chapter › Communication
Glucagon-like peptide-1 (GLP-1) is a key hormone for regulation of blood glucose and satiety in humans. It is produced by L-cells of the gut epithelium and is particularly known as an incretin hormone that reduces post prandial blood glucose levels by stimulation of insulin secretion in a glucose-dependent manner. But perhaps equally importantly, GLP-1’s glucose lowering effects are attributable to a strong inhibition of glucagon secretion, and, thereby, a reduction of hepatic glucose output. The effects of GLP-1 on insulin secretion are mediated by binding of the hormone to the receptor (GLP-1r) on the pancreatic β-cell, which increases intracellular cAMP levels and sets in motion a plethora of events that lead to secretion. In contrast, the inhibitory effect of GLP-1 on the α-cell may be indirect, involving paracrine intra-islet regulation by somatostatin and possibly also insulin, although GLP-1 also inhibits glucagon secretion in patients with type 1 diabetes mellitus. Besides these acute effects on the endocrine pancreas, GLP-1 also appears to have a positive effect on β-cell mass. In the following we will review GLP-1’s pancreatic effects with particular focus on its effects on pancreatic islets hormone secretion.
- Faculty of Health and Medical Sciences - Glucagon-Like Peptide 1, Insulin, Glucagon, Somatostatin